Literature DB >> 22040163

Receptor tyrosine kinases: from biology to pathology.

Mouna Choura1, Ahmed Rebaï.   

Abstract

Receptor tyrosine kinases (RTKs) are transmembrane proteins involved in the control of fundamental cellular processes in metazoans. RTKs possess a general structure that includes an extracellular domain, a transmembrane domain and a highly conserved tyrosine kinase domain. RTKs are classified according to their variable extracellular ligand-binding domain. Studies of human RTK members have yielded a wealth of information elucidating their importance. Improper functioning of these enzymes due to mutations, mainly in the kinase domain, is often manifested in various human diseases and is known to be involved in several types of cancer. Here we summarize most of human RTKs, their cognate ligands, as well as related diseases and discuss the eventual use of certain RTKs as new therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22040163     DOI: 10.3109/10799893.2011.625425

Source DB:  PubMed          Journal:  J Recept Signal Transduct Res        ISSN: 1079-9893            Impact factor:   2.092


  21 in total

Review 1.  Extracellular assembly and activation principles of oncogenic class III receptor tyrosine kinases.

Authors:  Kenneth Verstraete; Savvas N Savvides
Journal:  Nat Rev Cancer       Date:  2012-10-18       Impact factor: 60.716

Review 2.  Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery.

Authors:  Omid Zarei; Silvia Benvenuti; Fulya Ustun-Alkan; Maryam Hamzeh-Mivehroud; Siavoush Dastmalchi
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-08       Impact factor: 4.553

Review 3.  Mutation-introduced dimerization of receptor tyrosine kinases: from protein structure aberrations to carcinogenesis.

Authors:  Huimin Hu; Yanwei Liu; Tao Jiang
Journal:  Tumour Biol       Date:  2015-03-07

Review 4.  Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics.

Authors:  Orit Jacobson; Xiaoyuan Chen
Journal:  Pharmacol Rev       Date:  2013-09-24       Impact factor: 25.468

5.  EGF Receptor and mTORC1 Are Novel Therapeutic Targets in Nonseminomatous Germ Cell Tumors.

Authors:  Kenneth S Chen; Nicholas J Fustino; Abhay A Shukla; Emily K Stroup; Albert Budhipramono; Christina Ateek; Sarai H Stuart; Kiyoshi Yamaguchi; Payal Kapur; A Lindsay Frazier; Lawrence Lum; Leendert H J Looijenga; Theodore W Laetsch; Dinesh Rakheja; James F Amatruda
Journal:  Mol Cancer Ther       Date:  2018-02-26       Impact factor: 6.261

Review 6.  MicroRNAs as Mediators of Resistance Mechanisms to Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumours.

Authors:  Michele Ghidini; Jens C Hahne; Melissa Frizziero; Gianluca Tomasello; Francesco Trevisani; Andrea Lampis; Rodolfo Passalacqua; Nicola Valeri
Journal:  Target Oncol       Date:  2018-08       Impact factor: 4.493

7.  Type II cGMP-dependent protein kinase inhibits activation of key members of the RTK family in gastric cancer cells.

Authors:  Lu Jiang; Yongchang Chen; Jianrong Sang; Yueying Li; Ting Lan; Ying Wang; Yan Tao; Hai Qian
Journal:  Biomed Rep       Date:  2013-03-21

8.  MET Suppresses Epithelial VEGFR2 via Intracrine VEGF-induced Endoplasmic Reticulum-associated Degradation.

Authors:  Tom T Chen; Ellen Filvaroff; Jing Peng; Scot Marsters; Adrian Jubb; Hartmut Koeppen; Mark Merchant; Avi Ashkenazi
Journal:  EBioMedicine       Date:  2015-03-28       Impact factor: 8.143

9.  BreastMark: an integrated approach to mining publicly available transcriptomic datasets relating to breast cancer outcome.

Authors:  Stephen F Madden; Colin Clarke; Patricia Gaule; Sinead T Aherne; Norma O'Donovan; Martin Clynes; John Crown; William M Gallagher
Journal:  Breast Cancer Res       Date:  2013       Impact factor: 6.466

10.  Morphine Prevents Ischemia/Reperfusion-Induced Myocardial Mitochondrial Damage by Activating δ-opioid Receptor/EGFR/ROS Pathway.

Authors:  Jingman Xu; Xiyun Bian; Huanhuan Zhao; Yujie Sun; Yanyi Tian; Xiaodong Li; Wei Tian
Journal:  Cardiovasc Drugs Ther       Date:  2021-07-19       Impact factor: 3.947

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.